$135 Million

CTI BioPharma

Sole Placement Agent and Financial Advisor, August 2021

Senior Term Loan & Revenue Participation Right (Synthetic Royalty) Sale

CTI BioPharma (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, CTI focuses on developing and commercializing Pacritinib, its product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis, and in response to the COVID pandemic, severe COVID-19 disease. CTI is headquartered in Seattle, Washington

More Like This

May 2022

Sale of GeneDx, Inc., a Subsidiary of OPKO Health, Inc. (NASDAQ: OPK) to Sema4 Holdings Corp. (SMFR)

Financial Advisor

View Details
Apr 2022
$225 Million

Senior Secured Term Loan

Sole Placement Agent & Exclusive Financial Advisor

View Details
Apr 2022
$73.1 Million

Registered Direct Offering

Bookrunner

View Details